- Previous Close
1.6200 - Open
1.6200 - Bid 1.6400 x --
- Ask 1.6600 x --
- Day's Range
1.6200 - 1.7200 - 52 Week Range
1.4800 - 4.2600 - Volume
87,177 - Avg. Volume
65,783 - Market Cap (intraday)
135.462M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date Mar 31, 2025 - Apr 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
www.cardiolrx.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CRDL.TO
View MorePerformance Overview: CRDL.TO
Trailing total returns as of 3/13/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRDL.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRDL.TO
View MoreValuation Measures
Market Cap
135.46M
Enterprise Value
119.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
12.99
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-79.07%
Return on Equity (ttm)
-159.53%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.14M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
15.89M
Total Debt/Equity (mrq)
1.59%
Levered Free Cash Flow (ttm)
-12.15M